Q-omics provides the consensus-scored C1orf68 profile across patient tissues and cancer cell-line models. C1orf68 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, C1orf68 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, C1orf68 RNA expression shows 8,938 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ESCA, and LUSC as cancer lineages where C1orf68 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf68 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf68 survival associations across molecular data types. C1orf68 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf68 RNA expression–survival associations across cancer types. High C1orf68 expression shows unfavorable associations in THYM, KIRP, UVM, SKCM and READ, but favorable associations in ESCA. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .022). Together, the overview and detailed table identify ESCA as the clearest survival context for C1orf68 RNA expression.
This table summarizes C1orf68 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for C1orf68. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf68 shows lower tumor expression in PRAD and higher tumor expression in LUSC, HNSC and THCA. The LUSC box plot shows higher C1orf68 RNA expression in tumor versus normal tissue (log2 FC = +0.766, t-test p < 0.001).
This table shows molecular features associated with C1orf68 in patient tissues and cancer cell lines. In patient samples, C1orf68 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf68 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
